Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03030404|
Recruitment Status : Recruiting
First Posted : January 25, 2017
Last Update Posted : December 4, 2019
Gastric cancers are cancers of the stomach. Hereditary ones are passed from parent to child. Researchers want to gather data about hereditary gastric cancers. They want to learn about changes these cause in the body and about the genes involved.
-To gather data about hereditary gastric cancer.
- People at least 2 years old with personal or family history with a hereditary gastric cancer.
- People at least 2 years old with gene changes that lead to such cancer or a lesion that may be hereditary.
- Participants will be screened in a separate protocol.
Participants will have:
- Physical exam
- Medical history
- Blood tests
- Photos of skin lesions and other findings
- Gynecology consultation for women
- Cheek swab (some participants)
- For some participants, their relatives will be asked to join the study.
- Some participants will be asked to allow the study to get stored tissue samples for relatives who have died.
- Some samples will be sent to outside labs. All personal data will be protected. Samples will be destroyed when the study ends.
- Participants will get the results of genetic testing.
- Participants who cannot come to the NIH clinic may just give a cheek swab and have genetic testing done.
- Some participants will be contacted for more testing.
|Condition or disease|
|Stomach Neoplasms Stomach Cancer Familial Cancer Fundic Gland Polyposis Li-Fraumeni Syndrome Lynch Syndrome Peutz-Jeghers Syndrome|
- An estimated 1-3% of gastric cancer cases occur within a familial background as part of an inherited cancer syndrome
- Hereditary Diffuse Gastric Cancer (HDGC) is the most frequent form of familial gastric cancer and has been linked to a germline mutation in the CDH1 gene
- Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) is a more recently described autosomal dominant syndrome characterized by fundic gland polyposis with antral sparing
- Other syndromes that predispose to gastric cancer include Li-Fraumeni syndrome, Lynch syndrome, Peutz-Jeghers syndrome, familial adenomatous polyposis syndrome and others
- Characterize the natural and clinical histories of hereditary gastric cancer syndromes
- Individuals, and family members, who fulfill clinical criteria for a hereditary gastric cancer syndrome irrespective of previous genetic testing or treatment
- These rare families will be recruited to genetically confirm diagnosis and study the natural history of hereditary gastric cancers
- Genetic testing will be offered to gain appreciation of the effect of mutations on the relative activity of various germline and somatic mutations.
- We will determine if there is a relationship between mutation and disease phenotype.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer|
|Actual Study Start Date :||January 27, 2017|
|Estimated Primary Completion Date :||December 31, 2026|
|Estimated Study Completion Date :||December 31, 2026|
Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.
- Characterization of the natural and clinical histories of hereditary gastric cancer syndromes [ Time Frame: 10 years ]Characterization of the natural and clinical histories of hereditary gastric cancer syndromes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03030404
|Contact: NIH Foregut Team||(240) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|Principal Investigator:||Jeremy L Davis, M.D.||National Cancer Institute (NCI)|